Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company dedicated to the discovery and development of novel therapies for patients suffering from diseases of the central and peripheral nervous system. Headquartered in Bresso, near Milan, Italy, the company's mission is to deliver innovative treatments that enhance the quality of life for individuals with CNS disorders.

The company's product portfolio includes Xadago® (safinamide), a treatment for Parkinson's disease that has received marketing authorization in over 20 markets globally and is commercialized through strategic partnerships. Newron's lead development asset is evenamide, a first-in-class glutamate modulator currently in Phase III clinical development for the treatment of schizophrenia, including treatment-resistant schizophrenia.

In recent news, the US Food and Drug Administration (FDA) placed a hold on the enrollment of new patients in US sites for Newron's Phase III ENIGMA-TRS 2 study of evenamide. This action followed the notification of a sudden death of a study participant at a clinical site outside the United States, though the event was assessed by the investigator as unrelated to the study treatment. Newron is actively collaborating with the FDA to provide the necessary information to resolve the hold and resume enrollment in the US, while the global ENIGMA-TRS 1 study continues as planned. Stefan Weber serves as the Chief Executive Officer of Newron Pharmaceuticals.

Latest updates

Newron Pauses US Enrollment in Schizophrenia Trial After Sudden Death

Event summary

  • Newron Pharmaceuticals has paused enrollment of new patients in the US sites of its Phase III ENIGMA-TRS 2 study for evenamide, a treatment for treatment-resistant schizophrenia (TRS).
  • The pause follows the sudden death of a study participant outside the US; the investigator deemed the death unrelated to the study treatment.
  • An independent safety monitoring board has recommended the studies continue as designed, and ENIGMA-TRS 1, ongoing in 21 countries, remains active.
  • ENIGMA-TRS 2 has received regulatory approval in Argentina and India and is nearing approval in Colombia and Malaysia.
  • Newron expects to announce results from the 12-week primary endpoint assessment of ENIGMA-TRS 1 in QIV 2026.

The big picture

The pause in enrollment highlights the inherent risks associated with late-stage clinical trials, particularly in therapies targeting complex neurological conditions. Treatment-resistant schizophrenia carries a significantly elevated mortality risk, making patient safety paramount and increasing regulatory scrutiny. This event could delay Newron's potential entry into a market with significant unmet need and substantial commercial potential, given the limited treatment options currently available.

What we're watching

Regulatory Scrutiny
The FDA’s response and the information Newron provides will determine the timeline for resuming US enrollment, potentially impacting the trial’s overall duration and cost.
Clinical Trial Risk
Whether Newron can adequately address the FDA’s concerns and maintain patient confidence will be crucial for the successful completion of the ENIGMA-TRS program.
Market Perception
The incident and resulting pause could influence investor sentiment and the perceived risk profile of evenamide, potentially impacting Newron’s valuation.
CID: 3567